SK Chemicals Co. Ltd, and Janssen Korea Ltd, on 7 October announced the signing of a contract for the co-marketing of Mvix(Mirodenafil HCl).
Mvix is indicated for the treatment of erectile dysfunction (ED).
Both companies are going to start joint sales at home and abroad from the second half of 2010.
SK Chemicals expects that thanks to this contract, domestic and international marketing will be more improved than now and ongoing international licensing-out is likely to have a positive impact.
But these expectations have some kind of barriers in the Korean drug market.
Some experts said, "Althouh each of the erectile dysfunction drugs has a slightly different features, such as the stiffness and the duration of erection, but they have not a big difference in effectiveness."
To make matters worse, there are already a lot of erectile dysfunction drugs in the Korean drug market namely, 'Viagra(Pfizer)' 'Cialis(Lilly)' 'Zydena(Dong-A Pharmaceutical)''Levitra (Bayer)' and 'Yaila(Chong Kun Dang).
These drugs account for more than 96% of the market share, and there is rarely a place for Mvix in the Korean drug market. [헬스코리아뉴스]
◆ SK케미칼, 꼴찌 ‘엠빅스’ 살리기 "이번엔 통할까"
